目的 采用Meta分析系统评价18F-FDG PET/CT对非小细胞肺癌EGFR基因突变的诊断价值。方法 计算机检索PubMed、EMbase、The Cochrane Library、中国期刊全文数据库、万方数据库、中文科技期刊数据库,查找有关18F-FDG PET/CT对非小细胞肺癌EGFR基因突变的诊断性试验。由 2 位评价员按照纳入与排除标准独立筛选文献、提取资料和评价纳入研究的方法学质量后,采用Meta DiSc1.4软件进行Meta分析。结果 最终纳入16篇文献,非小细胞肺癌3308例。病理确诊为肺腺癌2914例(88.09%),其他病理类型394例(11.91%)。Meta分析结果示,SEN合并=0.57[95%CI(0.55,0.60)],SPE合并=0.65[95%CI(0.62,0.67)],+LR合并=1.82[95%CI(1.49,2.23)],-LR合并=0.67[95%CI(0.59,0.76)],DOR合并=2.93[95%CI(2.08,4.15)],AUC=0.6678。结论 18F-FDG PET/CT的SUVmax对NSCLC患者的EGFR突变有一定的预测能力,其特异度优于敏感度,可以用于EGFR突变的诊断。
Abstract
Objective To evaluate the diagnostic value of 18F-FDG PET/CT for EGFR gene mutation in non-small cell lung cancer with Meta analysis.Methods Databases that had been searched included PubMed, EMbase, the Cochrane Library, Chinese Journal Full-text Database, Wanfang Database, Chinese Science and Technology Database. Diagnostic tests related to EGFR gene mutation in non-small cell lung cancer and involving 18F-FDG PET/CT were investigated and analyzed. Meta-analysis was performed using Meta DiSc 1.4 software after two reviewers independently screened the literature for inclusion and exclusion criteria, extracted the data and evaluated the methodological quality of the included studies.Results 16 articles and 3308 cases of non-small cell lung cancer patients were included. Meta-analysis results showed that the incorporated SEN averaged 0.57[95% CI (0.55,0.60)], incorporated SPE 0.65[95% CI (0.62,0.67) CI (1.49,2.23)], incorporated LR 0.67[95% CI (0.59,0.76)], and incorporated DOR 2.93[95% CI (2.08,4.15)], while AUC was 0.6678.Conclusions SUVmax of 18F-FDG PET/CT is of predictive value for the mutation of EGFR in NSCLC patients with better specificity than sensitivity, which can be used to predict the mutation of EGFR in NSCLC patients.
关键词
非小细胞肺癌 /
PET/CT /
18F-FDG /
EGFR
Key words
non-small cell lung cancer /
PET/CT /
18F-FDG /
EGFR
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] Dela Cruz C S, Tanoue L T, Matthay R A. Lung cancer: epidemiology, etiology, and prevention [J]. Clinics in Chest Medicine, 2011, 32(4): 605-640.
[2] Blandin K S, Crosbie P A, Balata H, et al. Progress and prospects of early detection in lung cancer [J]. Open Biology, 2017, 7(9): 170070.
[3] Nan X, Chao X, Yu X, et al. EGFR TKI as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer [J]. Oncotarget, 2017, 8(43): 75712.
[4] An Na,Zhang Yingshi,Niu Huibin. EGFR-TKIs versus taxanes agents in therapy for nonsmall-cell lung cancer patients [J]. Medicine, 2016, 95(50):e5601
[5] 程 凯, 葛鲁娜, 付 正. 肺癌18F-FDG PET/CTSUVmax值与临床因素及肿瘤标志物相关性研究 [J]. 中华肿瘤防治杂志, 2016, 23(13): 884-887.
[6] 李国平, 谢宝松, 周 硕. 标准摄取最大值对非小细胞肺癌患者无进展生存期的预测价值分析 [J]. 福建医药杂志, 2016, 38(2): 10-13.
[7] Wang D, Zhang M, Gao X, et al. Prognostic value of baseline 18F-FDG PET/CT functional parameters in patients with advanced lung adenocarcinoma stratified by EGFR mutation status [J]. PLoS ONE, 2016, 11(6): e0158307.
[8] Sun L, Pan W M, Luo Z M, et al. Clinical value of ~(18)F-FDG PET/CT in assessing suspicious relapse after rectal cancer resection [J]. World J Gastrointestinal Oncol, 2009, 1(1): 55-61.
[9] Miao Z, Ren G, Liu H, et al. PET of EGFR Expression with an 18F-Labeled Affibody Molecule [J]. J Nucl Med, 2012, 53(7): 1110-1118.
[10] Arthur C, Jin H, Wha M Y, et al. Correlation between EGFR gene mutation, cytologic tumor markers, 18F-FDG uptake in non-small cell lung cancer [J]. BMC Cancer, 2016, 16(1): 1-8.
[11] Na II, Byun B H, Kim K M, et al. 18F-FDG uptake and EGFR mutations in patients with non-small cell lung cancer: a single-institution retrospective analysis [J]. Lung cancer (Amsterdam, Netherlands), 2010, 67(1): 76-80.
[12] Huang C T, Yen R F, Cheng M F, et al. Correlation of F-18 fluorodeoxyglucose-positron emission tomography maximal standardized uptake value and EGFR mutations in advanced lung adenocarcinoma [J]. Med Oncol, 2010, 27(1): 9-15.
[13] Liu A, Han A, Zhu H, et al. The role of metabolic tumor volume (MTV) measured by [18F] FDG PET/CT in predicting EGFR gene mutation status in non-small cell lung cancer [J]. Oncotarget, 2017, 8(20): 33736.
[14] Dinnes J, Deeks J, Kirby J, et al. A methodological review of how heterogeneity has been examined in systematic reviews of diagnostic test accuracy [J]. Health Technol Assess, 2005, 9(12): 100-113.
[15] Mak R H, Digumarthy S R, Muzikansky A, et al. Role of 18F-fluorodeoxyglucose positron emission tomography in predicting epidermal growth factor receptor mutations in non-small cell lung cancer [J]. Oncologist, 2011, 16(3): 319-326.
[16] 张亚锐, 张 旭, 胡莹莹, 等. 非小细胞肺癌~(18)F-FDG摄取与EGFR突变的关系[J]. 中山大学学报(医学科学版), 2011, 32 (5): 674-678.
[17] Lee S M, Bae S K, Jung S J, et al. FDG uptake in non-small cell lung cancer is not an independent predictor of EGFR or KRAS mutation status: a retrospective analysis of 206 patients [J]. Clin Nucl Med, 2015, 40(12): 950-958.
[18] Cho A, Hur J, Moon Y W, et al. Correlation between EGFR gene mutation, cytologic tumor markers, 18F-FDG uptake in non-small cell lung cancer [J]. BMC Cancer, 2016, 16 (1) :1-8.
[19] Guan J, Xiao N J, Chen M, et al. 18F-FDG uptake for prediction EGFR mutation status in non-small cell lung cancer [J]. Medicine, 2016, 95(30): e4421.
[20] Kanmaz Z D, Aras G, Tuncay E, et al. Contribution of 18 Fluorodeoxyglucose positron emission tomography uptake and TTF-1 expression in the evaluation of the EGFR mutation in patients with lung adenocarcinoma [J]. Cancer Biomark, 2016, 16(3): 489-498.
[21] 强光亮, 续 蕊, 刘 杰, 等. 肺腺癌组织学亚型与18F-脱氧葡萄糖摄取值及表皮生长因子受体突变的关系 [J].中华胸心血管外科杂志, 2016, 32 (3):165-170.
[22] Lv Z, Fan J, Xu J, et al. Value of (18)F-FDG PET/CT for predicting EGFR mutations and positive ALK expression in patients with non-small cell lung cancer: a retrospective analysis of 849 Chinese patients [J]. Eur J Nucl Med Mol Imaging,2017,11:21.
[23] Takamochi K, Mogushi K, Kawaji H, et al. Correlation of EGFR or KRAS mutation status with 18F-FDG uptake on PET-CT scan in lung adenocarcinoma [J]. PLoS ONE, 2017, 12(4): e0175622.
[24] 丁德芹, 李 澄, 刘 璐, 等. 非小细胞肺癌患者EGFR突变与PET/CT 18F-FDG摄取之间的相关性[J].东南大学学报(医学版), 2017,36( 5):760-763.
[25] 丁重阳, 杨文平, 郭 喆,等. 18F-FDG PET-CT显像预测肺腺癌人表皮生长因子受体突变的价值[J].中华肿瘤杂志, 2017, 39(7): 528-531.
[26] 汤 泊, 丁重阳, 李天女. ~(18)F-FDG PET-CT显像在预测不可切除肺腺癌EGFR突变的价值[J]. 临床肿瘤学杂志, 2017, 22 (6) :526-530.
[27] 王 峥, 司婧文, 迟明友,等. 肺腺癌患者的EGFR基因突变与PET/CT的18F-FDG摄取值的相关性研究[J]. 转化医学电子杂志, 2017, 4 (9) :32-35.
[28] 刘晓晴, 郭万峰, 陈克能, 等. 研究进展加大临床实践的变革步伐 2014年NSCLC指南更新解读[J]. 浙江医学, 2014, 36 (8) :637-639.
[29] Yip SSF, Kim J, Coroller TP, et al. Associations between somatic mutations and metabolic imaging phenotypes in non-small cell lung cancer [J]. J Nuclear Med, 2017, 58(4): 569-576.
基金
武警后勤学院附属医院种子基金资助项目(FYQ201601)
PDF(833 KB)
